secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2023-02-03T23:59:59+00:00
Accession:  0001804220-23-000005
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q4 revenue down 31% to $3.41B, core up 14%; GAAP EPS $10.50
---------------------------------------------------------------------

- Q4 total revenues $3.41B (-31% YoY); ex-REGEN-COV/Ronapreve up 14% to $3.02B.
- GAAP diluted EPS $10.50 (Q4) and $38.22 (FY); non-GAAP $12.56 (Q4) and $44.98 (FY).
- EYLEA U.S. net sales $1.50B Q4 (-3%), FY $6.26B (+8%); Dupixent global net sales $2.45B Q4 (+38%), FY $8.68B (+40%).
- Aflibercept 8 mg BLA submitted for wet AMD/DME in Dec 2022; FDA approved Libtayo+chemo for NSCLC; EC approved Dupixent for prurigo nodularis and EoE.
- New $3.0B share repurchase program authorized Jan 2023; FY2023 guidance: non-GAAP R&D $3.725-3.925B, non-GAAP SG&A $2.130-2.280B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000180422023000005/0001804220-23-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000180422023000005/regn-20230203.htm
  HTML page:      https://secwatch.observer/filing/0001804220-23-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer